The trial will evaluate the safety and efficacy of HuCNS-SC cells as a treatment for dry AMD. These cells are a purified population of human neural stem cells that can self-renew and differentiate into the three major cell types. Currently, there is no approved treatment for dry AMD.
Related Articles on Ophthalmology:
Ophthalmologists Have More Musculoskeletal Disorders Than Other Physicians
Researchers Find Simple Surgery Fixes Crossed Eyes
FDA Approves Mobius Therapeutics’ Glaucoma Drug
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.